Trial · NCT02819804
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Dose-Limiting Toxicity (DLT) | Up to 28 days | Only one patient was treated on study and this patient did not complete the DLT period and was not evaluable for this outcome measure or any of the outcome measures. Sample size too small for analysis. | ||
| SECONDARY | Incidence of Adverse Events | Up to 28-days after the last dose | |||
| SECONDARY | Rate of Complete Hematologic Remission (CR) | At 84 days (3 cycles) | |||
| SECONDARY | Rate of Molecular Remission | At 84 days (3 cycles) | |||
| SECONDARY | Serum Level of Dasatinib | 24 hours after the start of cycle 1 and days 8, 15, and 22 prior to treatment during cycle 1 | |||
| SECONDARY | Serum Level of Nivolumab | Days 8, 15, and 22 prior to treatment during cycle 1 | |||
| SECONDARY | PD1 Expression Levels and Saturation Assessed in the Peripheral Blood | Baseline to 28-days after the last dose | |||
| SECONDARY | PD1 Expression Levels and Saturation in Bone Marrow | Baseline to 28-days after the last dose | |||
| SECONDARY | Peripheral T-cell Levels and Activation in Response to Treatment | At cycle 1 days: 1, 2, 8, 15, & 22 prior to dosing | |||
| OTHER_PRE_SPECIFIED | The 30 Day Mortality Rate | Up to 30 days | |||
| OTHER_PRE_SPECIFIED | Overall Survival (OS) | Up to 1 year | |||
| OTHER_PRE_SPECIFIED | Progression Free Survival (PFS) | Up to 1 year | |||
| OTHER_PRE_SPECIFIED | Duration of Remission (DOR) | Up to 1 year | |||
| OTHER_PRE_SPECIFIED | Compare the OS Between Patients Who Receive a Hematopoietic Stem Cell Transplant and Those Who Receive no Further Therapy Following Remission | Up to 1 year | |||
| OTHER_PRE_SPECIFIED | Presence of Resistance Mutations in Bone Marrow at the Time of Disease Progression | Up to 28-days after the last dose |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02819804/outcomes